(d) A surplus medication collection and distribution intermediary shall do all of the following:

1. (1) Create a registry, not to exceed 50 participating practitioners.

2. (2) Develop a donor form that may be in an electronic format and that shall include all of the following information:

   1. (A) The date the medication was donated.
   2. (B) The name, address, and telephone number of the donor.
   3. (C) The name, strength, and quantity of the medication.
   4. (D) The manufacturer and lot number, if applicable, of the medication.
   5. (E) The name and dated signature of the practitioner who is accepting and inspecting the donated medication.
   6. (F) An acknowledgment that the medication was handled and stored in accordance with the physician’s order and per the manufacturer’s recommendation.

3. (3) Develop a recipient form, which may be in an electronic format, and which shall include all of the following:

   1. (A) The date the recipient received the medication.
   2. (B) The name, address, and telephone number of the recipient.
   3. (C) The name, strength, and quantity of the medication.
   4. (D) The manufacturer and the lot number, if applicable, of the medication.
   5. (E) The name and dated signature of the practitioner who is accepting and inspecting the donated medication.
   6. (F) An acknowledgment that the donor is known to the practitioner and is a patient of record, and that there is no reason to believe that the donated prescription medication was improperly handled or stored.
   7. (G) An acknowledgment that by accepting the donated prescription medication, the recipient accepts any risks that an accidental mishandling could create.
   8. (H) An acknowledgment that the donor, the participating practitioner, and the surplus medication collection and distribution intermediary are released from liability arising from their participation pursuant to this article and the program established pursuant to Division 117 (commencing with Section 150400) of the Health and Safety Code.
   9. (I) An acknowledgment that the pharmaceutical manufacturer is released from liability of any claims or injury arising from the transfer of any prescription medication pursuant to this article and the program established pursuant to Division 117 (commencing with Section 150400) of the Health and Safety Code.
   10. (J) An acknowledgment that the recipient is receiving donated prescription medication and that the recipient is receiving the donated prescription medication at no cost.

(i) For purposes of this section, the following definitions apply:

1. (1) “Donor” means an individual who donates unused prescription medications to a participating practitioner for the purpose of redistribution to established patients of that practitioner.
2. (2) “Ineligible drugs” means drugs that are not able to be accepted for redistribution as part of the program established pursuant to Division 117 (commencing with Section 150400) of the Health and Safety Code. “Ineligible drugs” include all controlled substances, including all opioids, all compounded medications, injectable medications, drugs that have an approved United States Food and Drug Administration Risk Evaluation and Mitigation Strategy (REMS) requirement, and all growth factor medications.
3. (3) “Participating practitioner” means a person who is licensed to practice medicine by the Medical Board of California and is board certified in medical oncology or hematology and is registered with a surplus medication collection and distribution intermediary.
4. (4) “Recipient” means an individual who voluntarily receives donated prescription medications.
5. (5) “Unused cancer medication” or “medication” means a medication or drug, including a “dangerous drug” as defined in Section 4022 or a “drug” as defined in Section 4025, that is prescribed as part of a cancer treatment plan and is in its original unopened, tamper-evident dose unit packaging that includes the drug’s lot number and expiration date. A cancer drug packaged in single-unit doses may be accepted and dispensed if the outside packaging is opened but the single-unit dose packaging is unopened.